Your Web Site
Boston Scientific has 45% U.S. market share for stents
NEW YORK (MarketWatch) -- Boston Scientific Corp. said Tuesday that it estimates its September U.S. market share at 25% for its Promus everolimus-eluting coronary stent system and 19% for its Taxus Express2 paclitaxel-eluting...
